These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31571914)

  • 21. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways.
    Li B; Zhang X; Ren Q; Gao L; Tian J
    Front Pharmacol; 2021; 12():781623. PubMed ID: 35082669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
    Liu TJ; Koul D; LaFortune T; Tiao N; Shen RJ; Maira SM; Garcia-Echevrria C; Yung WK
    Mol Cancer Ther; 2009 Aug; 8(8):2204-10. PubMed ID: 19671762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.
    Zhang CΗ; Awasthi N; Schwarz MA; Schwarz RE
    Int J Oncol; 2013 Nov; 43(5):1627-35. PubMed ID: 24042258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.
    Ishikawa C; Senba M; Mori N
    Oncol Lett; 2018 Apr; 15(4):5311-5317. PubMed ID: 29552172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
    Rosich L; Montraveta A; Xargay-Torrent S; López-Guerra M; Roldán J; Aymerich M; Salaverria I; Beà S; Campo E; Pérez-Galán P; Roué G; Colomer D
    Oncotarget; 2014 Aug; 5(16):6788-800. PubMed ID: 25216518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
    Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    Yang X; Niu B; Wang L; Chen M; Kang X; Wang L; Ji Y; Zhong J
    Oncol Lett; 2016 Jul; 12(1):102-106. PubMed ID: 27347108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway.
    Liu X; Xie C; Li A; Zhang Y; Liu X; Zhou S; Shen J; Huo Z; Cao W; Ma Y; Xu R; Xing Y; Xie Y; Cai S; Tang X
    Am J Transl Res; 2019; 11(12):7255-7271. PubMed ID: 31934276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer.
    Hong B; Wang H; Deng K; Wang W; Dai H; Yan Lui VW; Lin W
    Oncotarget; 2017 Dec; 8(63):106486-106498. PubMed ID: 29290965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.
    Du W; Gao A; Herman JG; Wang L; Zhang L; Jiao S; Guo M
    Cancer Sci; 2021 Jul; 112(7):2870-2883. PubMed ID: 33931924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
    Zhu W; Fu W; Hu L
    Cancer Biother Radiopharm; 2013 Nov; 28(9):665-73. PubMed ID: 23768063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
    Cao W; Liu X; Zhang Y; Li A; Xie Y; Zhou S; Song L; Xu R; Ma Y; Cai S; Tang X
    Biomed Res Int; 2021; 2021():5556306. PubMed ID: 33987439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation.
    Sun Z; Li Q; Zhang S; Chen J; Huang L; Ren J; Chang Y; Liang Y; Wu G
    Onco Targets Ther; 2015; 8():269-77. PubMed ID: 25674002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
    Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
    Dey N; Sun Y; Carlson JH; Wu H; Lin X; Leyland-Jones B; De P
    Am J Cancer Res; 2016; 6(4):714-46. PubMed ID: 27186427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.